Fabio Strazzeri studied Mathematics at the University of Cagliari, University of Pisa and Complutense University of Madrid. In 2018 he obtained his PhD on computational topology and geometry degree from University of Southampton (UK). He is now a Postdoctoral Researcher at Barcelona’s Institut de Robòtica i Informàtica Industrial.
James Schofield is an expert in Systems Biomedicine at the University of Southampton, applying and developing technologies to define molecular phenotypes and their underlying biological mechanisms from multi-'omics data.
Paul Skipp is Associate Professor/Director of Centre for Proteomic Research at the University of Southampton. He has specialist expertise in phenotyping and stratified medicine, with experience of clinical trials, biomarker development and multi-omics studies from design to delivery.
Ruben is an Associate Professor of Pure and Applied Mathematics within Mathematical Sciences at the University of Southampton. He is an expert in Algebraic Topology complex networks, and topological data analysis.
Scott is based in Belgium as an expert in strategic design and guidance of medical research consortia. He supports leadership and delivery of flagship consortium projects such as U-BIOPRED, AirPROM, eTRIKS, BTCURE, COPD MAP, ERICA COPD, HealthPros, and ERS SHARP CRC - in total more than 179 million euros in research funding.
Angelike Kefalas has more than 20 years of experience in the diagnostic, medical device and pharmaceutical industry. She
has a rich background in commercializing FDA-approved 510(k) products and selling to healthcare professionals,
hospitals, physicians, patients / consumers and payers. In addition, she has built high performing commercial launch
teams from the ground-up at several start-ups.
Before Pinpoint, Angelike was Head of Global Marketing and Communications at Medicines360, successfully launching LILETTA®, a 510(k) FDA and EMA-approved pharmaceutical drug-device product, with Mediciness360's co-promote partner Allergan. Before that, she was Vice President of Marketing at Amplify Health and Executive Director, Strategic Marketing at Tethys Bioscience, a molecular diagnostic company that commercialized and sold PreDx®, a 7 biomarker CLIA approved blood test. She also was the Director of Strategic Marketing, Market Research and Analytics at Abbott Diagnostics, relaunching the FreeStyle Glucose Meter, a POC consumer-driven med-device.
Throughout her career, Angelike has been involved in 7 product launches, 4 of which have been global. Angelike’s areas of expertise include: product and company positioning, developing go-to-market commercial strategy, optimizing sales growth, and business development.
Angelike holds an MBA from Columbia Business School, Columbia University, NY and a Masters degree from Haas Business School, University of California Berkeley (through a joint degree program). She also received her B.S. from Brandeis University in Molecular Biology.
Joann Rhodes: Translation and Strategic Support
Founder - Director: Transres Ltd
Joann is a translational pharmacologist with experience spanning the life sciences R&D eco-system, across industry, academia, and biotech working as a consultant and holding senior positions for the Virtual Bio-Incubator, as visiting industry fellow at Imperial College National Heart and Lung Institute, UCL and within the pharmaceutical industry. In her recent roles at MSD as chief of staff, she successfully built the strategy and operations to start-up the UK-Discovery centre for diseases of Ageing at The Crick Institute; and at Pfizer, as external innovation scout, Joann created global multi-disciplinary strategic partnerships for small molecules and gene therapy programmes which have resulted in rationale to enable 4 candidates to reach the clinic.
Joann holds an Executive MBA from Imperial College obtaining the Dean’s award for academic achievement and Joan Woodward award for Organisational behaviour. An MSc in translational medicine from Edinburgh. She has a keen interest in creation of a positive infrastructure, to aid commercialisation to harness novel technologies for future life science innovation.